



### Supplementary Figure S6. Efficacy of the MCT1/4 inhibitor syrosingopine on ATL cells.

(A and B) Cell proliferation assay (A) and viable cell numbers (B) for ATL cells (MT1 and HPB-ATL2) treated with syrosingopine (1µM, 5µM and 10µM; n=3). Values in comparison to the dimethyl sulfoxide (DMSO) group are shown.

(C) Flow cytometric analysis of apoptosis and dead cells at day 4 (representative dot plots) for ATL cells (TL-Om1 and ED) treated with syrosingopine (1µM, 5µM and 10µM; n=3).

(D and E) ATL cells (MT1 and HPB-ATL2) expel less lactate when treated with syrosingopine. Lactate was examined intracellularly (D) or extracellularly (E) after 4 days of syrosingopine treatment.

Results are plotted as mean  $\pm$  SD, using one-way ANOVA with post-hoc Dunnet test (A, B, D and E). \*\*p < 0.01, \*\*\*p < 0.001; ns, not significant.